A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn(University of California San Diego), Subrata Ghosh(University of Calgary), Julián Panés(Centro de Investigación Biomédica en Red), Ivana Vranić(Pfizer (United Kingdom)), Wenjin Wang(Pfizer (United States)), Wojciech Niezychowski(Pfizer (United States)), Séverine Vermeire, Olivier Dewit, Harald Peeters, Jiřı́ Stehlı́k, Tomáš Vaňásek, David Laharie, Jean Frédéric Colombel, M A Bigard, Márta Varga, Margit Zeher, János Novák, Béla Hunyady, Á Salamon, I Rácz, Paolo Gionchetti, Anna Kohn, Cosimo Prantera, Pieter Stokkers, Maria Słomka, Leszek Paradowski, Tomasz Arłukowicz, L Kuzela, Boris Baricky, Tibor Hlavatý, María Isabel Vera-Muñoz, Julián Panés(Centro de Investigación Biomédica en Red), Jordi Guardiola, C Probert, JL Shaffer, Mark R. Fleisher, Ronald Edward Pruitt, William J. Sandborn(University of California San Diego), John S. Goff, John T. Weber, R. Bell, Andrew Zwick, Alexandra Gutierrez, Robert M. Levine, Stephen Brett Hanauer, Lori Ann Lavelle, Ravindranath Kottoor, Gerald W. Dryden, Robert Hardi, David Vaughn Glorioso, Prabhakar Swaroop, Scott D. Lee, Teressa Joan Patrick, Sheldon Scheinert, Charles A. Sninsky, Seymour Katz, Mark D. Noar, Marco Gaspari, Glenn L. Gordon, Thomas A. Dalton, Douglas Edward Homoky, William Ransom Kilgore, Joel A. Levien, Herbert R. Schneider, S. Moola, Frederik Cornelius Kruger, John Wright, Nazimuddin Aboo
Cited by 298
Abstract
Related Papers
No related papers found
Powered by citation graph analysis